Mayo Clinic researchers discover and manipulate molecular interplay that moves cancer cellsMarch 30, 2009JACKSONVILLE, Fla. - Based on research that reveals new insight into mechanisms that allow invasive tumor cells to move, researchers at the Mayo Clinic campus in Florida have a new understanding about how to stop cancer from spreading. A cancer that spreads elsewhere in the body, known as metastasis, is the process that most often leads to death from the disease. In the March 29 online issue of Nature Cell Biology, researchers say that a molecule known as protein kinase D1 (PKD1) is key to the ability of a tumor cell to "remodel" its structure, enabling it to migrate and invade. The researchers found that if PKD1 is active, tumor cells cannot move, a finding they say explains why PKD1 is silenced in some invasive cancers. During metastasis, invasive cancer cells respond to biological signals to move away from a primary tumor. Multiple research groups at Mayo Clinic in Florida are especially interested in this process. One team, led by cancer biologist Peter Storz, Ph.D., has been investigating a process known as actin remodeling at the leading edge - the most forward point - of these migrating tumor cells. "The events that reorganize the actin cytoskeleton at the leading edge are complex - a multitude of molecules act in concert," Dr. Storz says. "But it appears that PKD1 must be turned off if cancer cells are to migrate." Actin filaments help make up the cytoskeleton of cells. For cancer cells to move, the actin-based cell structure has to be continually reorganized, Dr. Storz says, and to do this, new actin filaments need to be generated to shift the cell forward. Dr. Storz' group discovered that PKD1 was critical to this process. The researchers found that PKD1 inhibits another protein known as slingshot, which regulates the severing of existing actin structures so that new actin filaments can be synthesized, an event that is essential for cell movement. The researchers used methods to deplete tumor cells of PKD1 and found that their motility increased. They then expressed activated PKD1 in tumor cells and found that movement was blocked. PKD1 is therefore a negative regulator of directed cell migration, and if PKD1 is not expressed in tumor cells, slingshot will become active and will contribute to the reorganization of actin, and a tumor cell will move, according to researchers. "This makes sense, because other investigators have found that PKD1 is down-regulated, or turned off, in invasive forms of gastric, prostate, and breast cancer," says Dr. Storz. So far, investigators have identified a number of players along the pathways that regulate cancer cell movement, from the molecule (RhoaA) that activates PKD1, to the well-known protein (cofilin) that disassembles actin filaments and which is regulated by slingshot. When PKD1 is activated, cofilin does not function and so the cell cannot move. "Now that we have identified PKD1 as key regulator in processes regulating actin-based directed tumor cell movement, we can begin to think about designing treatments to stop invasive cancer cells from metastasizing," says Dr. Storz. "The basic mechanisms we have uncovered are key to developing those strategies." Mayo Clinic |
|||||||||||||||||||||
| Related Tumor Cells Current Events and Tumor Cells News Articles New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Cancers' Sweet Tooth May Be Weakness The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. 'Cross-talk' mechanism contributes to colorectal cancer Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors. CSHL study shows that some malignant tumors can be shut down after all Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. New Notre Dame study provides insights into the molecular basis of tumor cell behavior A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression. Immune therapy can protect against or treat later lymphoma Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection. Study reveals a 'missing link' in immune response to disease The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery. Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. More Tumor Cells Current Events and Tumor Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||